| Authors: |
Abel GA; Dana-Farber Cancer Institute, Boston, MA, USA. gregory_abel@dfci.harvard.edu., Kim HT; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard School of Public Health, Boston, MA, USA., Hantel A; Dana-Farber Cancer Institute, Boston, MA, USA., Steensma DP; Dana-Farber Cancer Institute, Boston, MA, USA., Stone R; Dana-Farber Cancer Institute, Boston, MA, USA., Habib A; Dana-Farber Cancer Institute, Boston, MA, USA., Ho VT; Dana-Farber Cancer Institute, Boston, MA, USA., Wadleigh M; Dana-Farber Cancer Institute, Boston, MA, USA., El-Jawahri A; Massachusetts General Hospital, Boston, MA, USA., Alyea EP; Duke Cancer Institute, Durham, NC, USA., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA., Koreth J; Dana-Farber Cancer Institute, Boston, MA, USA., Antin JH; Dana-Farber Cancer Institute, Boston, MA, USA., Soiffer RJ; Dana-Farber Cancer Institute, Boston, MA, USA., Cutler C; Dana-Farber Cancer Institute, Boston, MA, USA. |
